Abstract: The present invention provides an industrially advantageous method of producing aminophenol compounds represented by the formula (1) by a simple and easy procedure at a high yield and a high purity.

Abstract: The present invention provides an industrially advantageous method of producing aminophenol compounds represented by the formula (1) by a simple and easy procedure at a high yield and a high purity.

Abstract: An electromagnetic wave absorption panel for use in building construction includes a protective tile layer, an absorber layer, a metal reflective layer, and a building support layer, such as concrete. The absorber layer is multi-component structure, such as: a high dielectric constant layer and ferrite layer; a ferrite layer and a low dielectric constant layer; a ferrite and a polymer; a polymer and a material having a higher dielectric constant than the polymer; a ferroelectric, a ferrite, and a polymer; a ferrite, a polymer, and a high dielectric constant material; and a high dielectric constant material, a material in which the imaginary part of the permeability is greater than or equal to the real part of the permeability, and a low dielectric constant material. The invention also includes combinations of the above, such as: a high dielectric constant material, a ferrite, and a low dielectric constant material; and multiple layers of a ferrite and a polymer.

Abstract: An electromagnetic wave absorption panel for use in building construction includes a protective tile layer, an absorber layer, a metal reflective layer, and a building support layer, such as concrete. The absorber layer utilizes novel materials including high dielectric constant materials, such as ABO.sub.3 type perovskites, layered superlattice materials, conducting oxides, and signet magnetics, ferroelectrics, such as ABO.sub.3 type perovskites and layered superlattice materials, garnets, a nickel-zinc ferrite, Ni.sub.0.4 Zn.sub.0.6 Fe.sub.2 O.sub.4, and polymer-ceramic composites of the above materials.

Abstract: This invention provides a condensed pyrazole derivative of the Formula (1): ##STR1## (where A denotes CH or N, R.sup.0 and R.sup.3 denote same or different, a hydrogen atom or a lower alkyl group, R.sup.1 and R.sup.2 denote same or different, a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m denotes 1 or 2, and n denotes 1, 2 or 3, provided that, when n is 2, two R.sup.2 may be connected to each other to form a lower alkylenedioxy group), or its pharmaceutically acceptable salt. This derivative or its salt is excellent in the effect of inhibiting the expression of action of androgen, thereby being excellent in therapeutical effect of benign prostatic hypertrophy, prostatic carcinoma, etc., and has a long lasting of efficacy and high oral absorption.

Abstract: The invention discloses a pyrimidien derivative expressed in Formula [I]: ##STR1## where R.sup.1 denotes a hydrogen atom or hydroxyl group, R.sup.2 denotes a hydrogen atom, lower alkoxycarbonyl group, lower alkoxy group, halogen atom, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, lower alkoxycarbonyl lower alkyl group, carboxyl group, carboxy lower alkyl group, group: --CONHR.sup.6 (R.sup.

Abstract: This invention provides a condensed pyrazole derivative of the Formula (1): ##STR1## (where A denotes CH or N, R.sup.0 and R.sup.3 denote same or different, a hydrogen atom or a lower alkyl group, R.sup.1 and R.sup.2 denote same or different, a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m denotes 1 or 2, and n denotes 1, 2 or 3, provided that, when n is 2, two R.sup.2 may be connected to each other to form a lower alkylenedioxy group), or its pharmaceutically acceptable salt. This derivative or its salt is excellent in the effect of inhibiting the expression of action of androgen, thereby being excellent in therapeutical effect of benign prostatic hypertrophy, prostatic carcinoma, etc., and has a long lasting of efficacy and high oral absorption.

Abstract: Pyrazolotriazine compounds of the formula: ##STR1## wherein R.sup.1 is OH or alkanoyloxy; R.sup.2 is H, OH, or SH; R.sup.3 is (1) unsaturated N- or S-containing heterocyclic group optionally having 1-2 substituents of halogen, nitro or phenylthio, (2) naphthyl, (3) phenyl optionally having 1-3 substituents of (i) alkyl, (ii) phenyl, (iii) alkoxycarbonyl, (iv) cyano, (v) nitro, (vi) alkoxy, (vii) phenylalkoxy (viii) phenylthio-alkyl, (ix) phenoxy, (x) ##STR2## R is alkyl, halo-substituted alkyl, phenyl optionally having 1-3 substituents, or pyridyl, and l is 0, 1 or 2, (xi) halogen, (xii) phenylalkyl, (xiii) carboxy, (xiv) alkanoyl, (xv) benzoyl optionally having 1-3 substituents, (xvi) amino, (xvii) OH, (xviii) alkanoyloxy, (xix) ##STR3## or (xx) ##STR4## (A is alkylene), said compounds having a xanthine oxidase inhibitory activity and are useful for the prophylaxis and treatment of gout.